TG Therapeutics Inc TGTX

NAS: TGTX | ISIN: US88322Q1085   21:23
16,45 USD (-5,60%)
(-5,60%)   21:23

4 augustus 2022 · TG THERAPEUTICS INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against TG Therapeutics Inc. (NASDAQ: TGTX); Lead Plaintiff Deadline is September 16 2022 · Persbericht

25 juli 2022 · Bronstein, Gewirtz & Grossman, LLC Notifies TG Therapeutics, Inc. (TGTX) Investors of Class Action and Encourages Investors to Contact the Firm · Persbericht

26 april 2021 · Samsung Biologics and TG Therapeutics Expand Collaboration for the Large Scale Manufacture of Ublituximab · Persbericht

9 maart 2021 · TG Therapeutics Announces Publication of Results from the UNITY-NHL Phase 2b Trial Evaluating Umbralisib Monotherapy in Patients with Relapsed or Refractory Indolent non-Hodgkin Lymphoma in the Journal of Clinical Oncology · Persbericht

4 maart 2021 · TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting · Persbericht

26 februari 2021 · TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update · Persbericht

23 februari 2021 · TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia in The Lancet Haematology · Persbericht

5 februari 2021 · TG Therapeutics Announces FDA Accelerated Approval of UKONIQ™ (umbralisib) · Persbericht

15 januari 2021 · TG Therapeutics to Participate in the B. Riley Securities Oncology Investor Conference · Persbericht

8 januari 2021 · TG Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties